Technical Guide: Hoechst 33342/PI Double Staining Kit (K2237
2026-05-06
The Hoechst 33342/PI Double Staining Kit enables rapid, dual-fluorescence discrimination between viable, apoptotic, and necrotic cells in basic research workflows. It should be used for microscopy-based cell death assays and is not intended for diagnostic or clinical applications.
Vardenafil HCl Trihydrate: Real-World PDE5 Selectivity and P
2026-05-06
Explore how Vardenafil HCl Trihydrate enables accurate PDE5 inhibition and cGMP signaling pathway studies. This article uniquely addresses proteoform complexity in functional assays, bridging molecular selectivity and experimental reliability.
Calpeptin: Beyond Fibrosis—Precision Modulation of Cell Sign
2026-05-05
Explore how Calpeptin, a potent calpain inhibitor, enables next-generation control over cell signaling, extracellular vesicle biology, and disease modeling. This article provides an advanced scientific perspective on Calpeptin’s applications, bridging key findings in EV inhibition with practical assay guidance.
Cediranib (AZD2171): Quantitative Insights in VEGFR Inhibiti
2026-05-05
Explore Cediranib (AZD2171) as an angiogenesis inhibitor through a quantitative, evidence-driven lens. This article uniquely bridges advanced in vitro evaluation methodologies with practical assay optimization for cancer research.
Dorsomorphin (Compound C): Precision Inhibition in Pathway S
2026-05-04
Dorsomorphin (Compound C) from APExBIO enables selective and reversible inhibition of AMPK and BMP signaling, transforming metabolic, autophagy, and differentiation research. Explore optimized protocols, troubleshooting strategies, and actionable insights for robust experimental control across diverse cell and animal models.
SB743921: Potent Kinesin Spindle Protein Inhibitor for Cance
2026-05-04
SB743921 is a highly potent and selective kinesin spindle protein inhibitor. It induces cell cycle arrest in mitosis, leading to apoptosis in diverse cancer cell lines. Its nanomolar activity and selectivity make it an advanced tool for preclinical cancer research.
Pioglitazone (SKU B2117): Reliable PPARγ Agonist for Assay P
2026-05-03
Explore how Pioglitazone (SKU B2117) from APExBIO addresses real-world laboratory challenges in cell viability, inflammatory process modulation, and metabolic disorder research. This article presents scenario-driven solutions, protocol parameters, and evidence-backed recommendations to improve reproducibility and interpretability in advanced biomedical workflows.
Tamoxifen as a Selective Estrogen Receptor Modulator: Applie
2026-05-02
Tamoxifen’s versatility as a selective estrogen receptor modulator extends from breast cancer research to gene editing, kinase inhibition, and emerging antiviral studies. This article provides workflow-driven guidance, practical troubleshooting, and experimental enhancements for advanced laboratories leveraging APExBIO’s high-purity Tamoxifen (SKU B5965).
Halazone (SKU BA1377): Evidence-Based Solutions for Lab Assa
2026-05-02
This article presents scenario-driven, evidence-based guidance for using Halazone (SKU BA1377) as an antimicrobial sulfonamide derivative in water disinfection and neurophysiological assays. Bench scientists and biomedical researchers will find validated protocols, data interpretation tips, and candid product selection advice, all grounded in quantitative data and peer-reviewed sources. Explore how Halazone provides reproducible performance and workflow reliability in demanding laboratory settings.
Angiotensin I: Strategic Mechanisms for Translational Impact
2026-05-01
This thought-leadership article unpacks the mechanistic, experimental, and translational landscape of Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) as a pivotal molecular gateway in cardiovascular, neuroendocrine, and drug discovery models. We synthesize new cross-domain implications from recent SARS-CoV-2 binding data, provide protocol parameters, critically position APExBIO’s Angiotensin I offering, and forecast future research pipelines for the renin-angiotensin system.
Strategic Use of Selective BCL-XL Inhibitor A-1155463 in Tra
2026-04-30
This thought-leadership article provides a mechanistic and strategic roadmap for translational researchers leveraging the selective BCL-XL inhibitor A-1155463. It synthesizes the latest mechanistic insights on BCL-XL’s role in apoptosis resistance, highlights key preclinical validation data, evaluates the competitive BH3-mimetic landscape, and offers actionable protocol guidance. By contextualizing A-1155463 within emerging evidence—including enhanced apoptotic priming in glioblastoma and other solid tumors—this piece advances beyond product-centric overviews to offer nuanced, evidence-driven recommendations for preclinical and translational workflows.
Calpain Inhibitor I, ALLN: Technical Guide for Lab Workflows
2026-04-30
Calpain Inhibitor I, ALLN (SKU A2602) is a potent, selective inhibitor of calpain and cathepsin proteases, enabling precise control of proteolytic activity in models of apoptosis, inflammation, and ischemia-reperfusion injury. It is not suitable for diagnostic or medical applications, and careful attention to solubility and storage is essential for experimental reliability.
TCAIM Modulates OGDH and Mitochondrial Metabolism via Proteo
2026-04-29
Wang et al. identify TCAIM as a mitochondrial DNAJC co-chaperone that binds and reduces levels of a-ketoglutarate dehydrogenase (OGDH) through a post-translational mechanism involving HSPA9 and LONP1. This novel regulatory axis alters TCA cycle activity and mitochondrial metabolism, providing new insights relevant to metabolic and neurodegenerative disease research.
Strategic CXCR4 Antagonism: Translational Roadmap for AMD-07
2026-04-29
This thought-leadership article provides translational researchers with a mechanistic deep dive and strategic guide to deploying Mavorixafor hydrochloride (AMD-070 hydrochloride) as a CXCR4 antagonist. We integrate mechanistic rationale, clinical sequencing guidance, and experimental strategy, leveraging the latest clinical and workflow evidence. By contrasting the competitive landscape and highlighting the unique strengths of APExBIO’s offering, this piece offers actionable insights for advancing research in immunology, oncology, and virology.
Lycopene Mitigates DON-Induced Gut Injury via ERK Pathway Mo
2026-04-28
This study demonstrates that lycopene, a dietary carotenoid, reverses deoxynivalenol (DON)-induced intestinal barrier dysfunction and NLRP3 inflammasome activation in IPEC-J2 cells by targeting the ERK signaling pathway. These findings highlight new mechanistic insights and experimental protocols relevant for mycotoxin research and intestinal barrier studies.
509 records 23/34 page Previous Next First page 上5页 2122232425 下5页 Last page